WHI-P131 is an inhibitor of JAK3 and EGFR that exhibits anticancer chemotherapeutic, chemopreventive, anti-inflammatory, and anti-diabetic properties. WHI-P131 is prophylactic against carcinogenesis induced by UVB exposure in vivo, delaying lesion appearance and decreasing lesion volume and number. WHI-P131 decreases plasma creatine kinase and lactate dehydrogenase activity, decreasing infarct size, myocardial apoptosis and deterioration, and inflammation in animal models of ischemia. Additionally, WHI-P131 decreases TNF-α-induced expression of ICAM-1, VCAM-1, and fractalkine, improving myocardial permeability in cellular models. WHI-P131 displays potential as a prophylactic treatment for diabetes, as its inhibition of JAK3 and suppression of NF-κB results in decreased production of NO and iNOS, preventing destruction of pancreatic islet cells.